Mersana Therapeutics (NASDAQ: MRSN) reported Q3 EPS of ($0.35), $0.01 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $7.7 million versus the consensus estimate of $9.3 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.